|
Market Closed -
OTC Markets
13:41:16 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 0.8000 USD | -5.88% |
|
-.--% | -20.00% |
| 09-25 | Transgene provides update on its operations |  |
| 09-08 | Transgene Expands ProBioGen Partnership With Additional License | MT |
Company Valuation: Transgene
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 247.8 | 164.8 | 137.8 | 89.75 | 262.9 | 193.6 | - | - |
| Change | - | -33.52% | -16.38% | -34.86% | 192.89% | -26.34% | - | - |
| Enterprise Value (EV) 1 | 214.9 | 151.4 | 139.4 | 83.48 | 153.1 | 124.4 | 185.9 | 212.2 |
| Change | - | -29.53% | -7.95% | -40.12% | 83.37% | -18.71% | 49.42% | 14.14% |
| P/E | -12.1x | -5.02x | -6.23x | -2.34x | -3.69x | -5.05x | -3.21x | -7.86x |
| PBR | 3.69x | 4.38x | 8.82x | 5.92x | 1.14x | 2.36x | 8.84x | -70.7x |
| PEG | - | -0.1x | 0.2x | -0.1x | 0.4x | 0.1x | -0.1x | 0.1x |
| Capitalization / Revenue | 14.2x | 15.9x | 17.4x | 14.1x | 36.5x | 26.9x | 26.9x | 3.39x |
| EV / Revenue | 12.3x | 14.6x | 17.6x | 13.1x | 21.2x | 17.3x | 25.8x | 3.71x |
| EV / EBITDA | -10.2x | -5.37x | -4.9x | -2.43x | -4.54x | -2.85x | -2.65x | -8.99x |
| EV / EBIT | -9.14x | -5.06x | -4.64x | -2.34x | -4.37x | -2.81x | -2.63x | -7.24x |
| EV / FCF | -6.59x | -6.94x | -1,408x | -3.12x | -1.07x | -3.13x | -3.08x | -8.46x |
| FCF Yield | -15.2% | -14.4% | -0.07% | -32% | -93.4% | -31.9% | -32.5% | -11.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.21 | -0.33 | -0.22 | -0.29 | -0.26 | -0.14 | -0.22 | -0.09 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 17.41 | 10.34 | 7.9 | 6.353 | 7.21 | 7.2 | 7.2 | 57.2 |
| EBITDA 1 | -21 | -28.22 | -28.48 | -34.38 | -33.73 | -43.6 | -70.1 | -23.6 |
| EBIT 1 | -23.52 | -29.9 | -30.05 | -35.66 | -35.06 | -44.3 | -70.8 | -29.3 |
| Net income 1 | -19.54 | -32.8 | -22.33 | -33.97 | -37.52 | -38.2 | -61.6 | -25.3 |
| Net Debt 1 | -32.93 | -13.31 | 1.629 | -6.274 | -109.8 | -69.2 | -7.7 | 18.6 |
| Reference price 2 | 2.5400 | 1.6580 | 1.3700 | 0.6800 | 0.9600 | 0.7070 | 0.7070 | 0.7070 |
| Nbr of stocks (in thousands) | 97,576 | 99,370 | 100,566 | 131,990 | 273,827 | 273,882 | - | - |
| Announcement Date | 3/16/22 | 3/16/23 | 3/27/24 | 3/27/25 | 3/24/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.73x | 7.77x | 15.6x | 1.37% | 74.69B | |
| 30.56x | 8.79x | 27.4x | 0.04% | 58.81B | |
| 33.6x | 6.04x | 18.08x | 0.96% | 48.45B | |
| -20.7x | 214.73x | -22.18x | -.--% | 42.84B | |
| 33.49x | 3.25x | 14.04x | -.--% | 42.79B | |
| 48.17x | 5.48x | 30.1x | -.--% | 41.25B | |
| 27.6x | 7.84x | 20.39x | 0.41% | 31.13B | |
| 35.01x | 7.5x | 19.48x | -.--% | 30.28B | |
| -14.91x | 5.52x | -6.94x | -.--% | 24.05B | |
| Average | 21.62x | 29.66x | 12.89x | 0.31% | 43.81B | |
| Weighted average by Cap. | 23.19x | 29.31x | 14.21x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TNG Stock
- TRGN.F Stock
- Valuation Transgene
Select your edition
All financial news and data tailored to specific country editions
